Message from Dr. Amanda Psyrri, Kestrel International Coordinating Investigator

Dear Investigators,

As the international co-PI of Kestrel, I would like to share with you my great enthusiasm for this randomized phase III study evaluating concurrent tremelimumab and  durvalumab vs durvalumab monotherapy vs standard of care (EXTREME) as first line treatment in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Διαβάστε περισσότερα